Abstract
Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Nature Reviews Neurology |
Vol/bind | 15 |
Udgave nummer | 6 |
Sider (fra-til) | 312-314 |
Antal sider | 3 |
ISSN | 1759-4758 |
DOI |
|
Status | Udgivet - 1 jun. 2019 |